Analysts have been eager to weigh in on the Healthcare sector with new ratings on Vertex Pharmaceuticals (VRTX) and Veracyte (VCYT).
Vertex Pharmaceuticals (VRTX)
Needham analyst Alan Carr assigned a Hold rating to Vertex Pharmaceuticals today. The company’s shares closed last Thursday at $279.40.
According to TipRanks.com, Carr is a 2-star analyst with an average return of 0.4% and a 41.9% success rate. Carr covers the Healthcare sector, focusing on stocks such as Lexicon Pharmaceuticals, Phathom Pharmaceuticals, and ACADIA Pharmaceuticals.
Currently, the analyst consensus on Vertex Pharmaceuticals is a Strong Buy with an average price target of $314.21.
See today’s analyst top recommended stocks >>
Veracyte (VCYT)
Needham analyst Stephen Unger maintained a Buy rating on Veracyte today and set a price target of $37.00. The company’s shares closed last Thursday at $33.21, close to its 52-week high of $33.49.
According to TipRanks.com, Unger is a 5-star analyst with an average return of 25.5% and a 76.8% success rate. Unger covers the Healthcare sector, focusing on stocks such as Myriad Genetics, Thermo Fisher, and PerkinElmer.
The word on The Street in general, suggests a Moderate Buy analyst consensus rating for Veracyte with a $34.50 average price target.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
